Skip to main content
← All trials
Postoperative Pain, AcutePainDrugPhase 4

What this study is

The goal of this clinical trial is to explore alternative methods of postoperative pain control in Mohs micrographic surgery. The main aims are:

  • To provide more information to the Mohs surgery community regarding postoperative pain control.
  • Reducing pain improves the overall comfort and well-being of patients, leading to a better post-operative experience.
  • To provide patients with an alternative and potentially superior NSAID for pain control (compared to standard-of-care ibuprofen).

Researchers will compare 1) a single of dose Meloxicam 7.5 mg, followed by acetaminophen 500 mg; 2) a single dose of Meloxicam 15 mg, followed by acetaminophen 500 mg; 3) a single dose of acetaminophen 500 mg, followed by alternating ibuprofen 200 mg and acetaminophen 500 mg to see which better moderate pain control and patient satisfaction.

Participants will be asked to complete pain and patient satisfaction surveys.

What's being tested

  • Meloxicam 7.5 mg

    Intervention · DRUG

    This intervention is the mandatory oral Meloxicam 7.5mg dose after Mohs closure.

  • Meloxicam 15 mg

    Intervention · DRUG

    This intervention is the mandatory oral Meloxicam 15mg dose after Mohs closure.

  • Acetaminophen 500mg

    Intervention · DRUG

    This randomized control group will take a mandatory one-time dose of 500 mg acetaminophen with alternating 200 mg ibuprofen and 500 mg acetaminophen (standard of care) every 3 hours for pain.

Study details

Official title
Meloxicam for Postoperative Pain in Mohs Micrographic Surgery
Sponsor
University of Oklahoma
Conditions
Postoperative Pain, Acute · Skin Cancer
Enrolling
300 people
Starts
2025-10-15
Est. completion
2026-08-02
Design
Open-label, randomized, parallel groups, Phase 4
Record
View on ClinicalTrials.gov ↗